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Background—Etomidate is a sedative-hypnotic that is often used in critically ill patients because
it provides superior hemodynamic stability. However it also binds with high affinity to 11β-
hydroxylase, potently suppressing synthesis of steroids by the adrenal gland that are necessary for
survival. We report the results of studies to define the pharmacology of (R)-ethyl 1-(1-
phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate), a pyrrole analogue of etomidate
specifically designed not to bind with high affinity to 11β-hydroxylase.
Methods—The hypnotic potency of carboetomidate was defined in tadpoles and rats using loss of
righting reflex assays. Its ability to enhance wild-type α1β2γ2L and etomidate-insensitive mutant
α1β2(M286W)γ2L human γ-aminobutyric acid type A receptor activities was assessed using
electrophysiological techniques. Its potency for inhibiting in vitro cortisol synthesis was defined
using a human adrenocortical cell assay. Its effects on in vivo hemodynamic and adrenocortical
function were defined in rats.
Results—Carboetomidate was a potent hypnotic in tadpoles and rats. It increased currents mediated
by wild-type, but not etomidate-insensitive mutant γ-aminobutyric acid type A receptors.
Carboetomidate was three orders of magnitude less potent an inhibitor of in vitro cortisol synthesis
by adrenocortical cells than was etomidate. In rats, carboetomidate caused minimal hemodynamic
changes and did not suppress adrenocortical function at hypnotic doses.
Conclusions—Carboetomidate is an etomidate analogue that retains many of etomidate’s
beneficial properties, but is dramatically less potent as an inhibitor of adrenocortical steroid synthesis.
Carboetomidate is a promising new sedative-hypnotic for potential use in critically ill patients in
whom adrenocortical suppression is undesirable.
Introduction
Etomidate is an intravenous (IV) sedative-hypnotic that is used to induce general anesthesia
and is distinguished from other agents by its minimal effects on cardiovascular function. 1-4
Consequently, it is often used in patients who are elderly or critically ill. Etomidate contains
an imidazole ring and in common with many other imidazole-containing drugs, it suppresses
the synthesis of adrenocortical steroids. 5-11 This suppression occurs even with administration
of subhypnotic etomidate doses and is extremely long lasting. 12,13 Such “chemical
adrenalectomy” precludes etomidate administration by continuous infusion to maintain
anesthesia in the operating room (or sedation in the intensive care unit) and has raised serious
concerns regarding the administration of even a single bolus for anesthetic induction in
critically ill patients. 14-19
This led us to search for solutions to the problem of etomidate-induced adrenocortical
suppression. In a previous study, we tested a pharmacokinetic strategy for reducing the duration
of adrenocortical suppression following bolus administration. We synthesized an analogue of
etomidate (methoxycarbonyl-etomidate) designed to be rapidly metabolized by esterases and
demonstrated that it does not produce prolonged adrenocortical suppression in rats following
bolus administration. 20
We have also considered pharmacodynamic strategies for reducing etomidate-induced
adrenocortical suppression. Etomidate suppresses adrenocortical steroid synthesis by
inhibiting 11β-hydroxylase, a cytochrome P450 enzyme that is required for the synthesis of
cortisol, corticosterone, and aldosterone. 21 X-ray crystallographic studies of other imidazole-
containing drugs to cytochrome P450 enzymes indicate that high affinity binding occurs
because the basic nitrogen in the drug’s imidazole ring coordinates with the heme iron in the
enzyme’s active site; cytochrome P450 enzymes (including 11β-hydroxylase) contain heme
prosthetic groups at their active sites. 22-24 Although 11β-hydroxylase has not yet been
crystallized nor its interaction with etomidate precisely defined, homology modeling studies
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suggest that high affinity binding of etomidate to 11β-hydroxylase also involves coordination
between the drug’s basic nitrogen and the enzyme’s heme iron (figure 1A). 25 This led us to
hypothesize that high affinity binding to 11β-hydroxylase (and thus adrenolytic activity) could
be “designed out” of etomidate without disrupting potent anesthetic and γ-aminobutyric acid
type A (GABAA) receptor activities by replacing this nitrogen with other chemical groups that
cannot coordinate with heme iron. Based on this hypothesis, we have designed and synthesized
(see Appendix 1) (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate) as
the lead compound in a new class of pyrrole-based sedative-hypnotic analogues of etomidate
designed not inhibit adrenocortical function at pharmacologically relevant doses (figure 1B).
Materials and Methods
Animals
All animal studies were conducted in accordance with rules and regulations of the
Subcommittee on Research Animal Care at the Massachusetts General Hospital, Boston,
Massachusetts. Early prelimb-bud stage Xenopus laevis tadpoles and adult female Xenopus
laevis frogs were purchased from Xenopus 1 (Ann Arbor, MI). Tadpoles were maintained in
our laboratory and frogs were maintained in the Massachusetts General Hospital Center for
Comparative Medicine animal care facility. Adult male Sprague-Dawley rats (300-500 gm)
were purchased from Charles River Laboratories (Wilmington, MA) and housed in the
Massachusetts General Hospital Center for Comparative Medicine animal care facility.
Blood draws and IV drug administrations used a lateral tail vein IV catheter (24 gauge, 19 mm)
placed under brief (approximately 1-5 min) sevoflurane or isoflurane anesthesia delivered
using an agent specific variable bypass vaporizer with continuous gas monitoring. Animals
were weighed immediately prior to IV catheter placement and were allowed to fully recover
from inhaled anesthetic exposure prior to study. During all studies, rats were placed on a
warming stage (Kent Scientific, Torrington, CT) that our previous studies showed maintains
rectal temperatures between 36-38 °C in anesthetized rats. 20
Loss of Righting Reflex (LORR)
Tadpoles—Groups of 5 early prelimb-bud stage Xenopus laevis tadpoles were placed in 100
ml of oxygenated water buffered with 2.5 mM Tris HCl buffer (pH = 7.4) and containing a
concentration of carboetomidate ranging from 1 – 40 μM. Tadpoles were manually tipped every
5 min with a flame polished pipette until the response stabilized. Tadpoles were judged to have
LORR if they failed to right themselves within 5 seconds after being turned supine. At the end
of each study, tadpoles were returned to fresh water to assure reversibility of hypnotic action.
The EC50 for LORR was determined from the carboetomidate concentration-dependence of
LORR using the method of Waud. 26
Rats—Rats were briefly restrained in a 3 inch diameter, 9 inch long acrylic chamber with a
tail exit port. The desired dose of carboetomidate in dimethyl sulfoxide (DMSO; typically at
40 mg/ml) was injected through a lateral tail vein catheter followed by an approximately 1 ml
normal saline flush. After injection, rats were removed from the restraint device and turned
supine. A rat was judged to have LORR if it failed to right itself (onto all four paws) after drug
administration. A stop-watch was used to measure the duration of LORR, which was defined
as the time from carboetomidate injection until the animal spontaneously righted itself. The
ED50 for LORR upon bolus administration was determined from the dose-dependence of
LORR using the method of Waud. 26
Onset time for LORR was determined separately by injecting rats with 28 mg/kg
carboetomidate (40 mg/ml in DMSO) or 4 mg/kg etomidate (5.7 mg/ml in DMSO) through a
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lateral tail vein catheter followed by an approximately 1 ml normal saline flush. Following
injection, rats were immediately removed from the restraint device and repeatedly turned
supine until they no longer spontaneously righted. The onset time was defined as the time from
injection until LORR occurred.
GABAA Receptor Electrophysiology
Adult female Xenopus laevis frogs were anesthetized with 0.2% tricaine (ethyl-
maminobenzoate) and hypothermia. Ovary lobes were then excised through a small laparotomy
incision and placed in OR-2 solution (82 mM NaCl, 2 mM KCl, 2 mM MgCl2, 5 mM HEPES,
pH 7.5) containing collagenase 1A (1 mg/ml) for 3 hrs to separate oocytes from connective
tissue.
Stage 4 and 5 oocytes were injected with messenger RNA encoding the α1, β2 (or β2(M286W)),
and γ2L subunits of the human GABAA receptor (~ 40 ng of messenger RNA total at a subunit
ratio of 1:1:2). This messenger RNA was transcribed from complementary DNA encoding for
GABAA receptor α1, β2 (or β2M286W), and γ2L subunits using the mMESSAGE mMACHINE
High Yield Capped RNA Transcription Kit (Ambion, Austin, Tx). Injected oocytes were
incubated in ND-96 buffer solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 0.8 mM
MgCl2, 10 mM HEPES, pH 7.5) containing 50 U/ml of penicillin and 50 μg/ml of streptomycin
at 17°C for at least 18 hours before electrophysiological experiments.
All electrophysiological recordings were performed using the whole cell two-electrode
voltage-clamp technique. Oocytes were placed in a 0.04 ml recording chamber and impaled
with capillary glass electrodes filled with 3 M KCl and possessing open tip resistances less
than 5 MΩ. Oocytes were then voltage-clamped at −50 mV using a GeneClamp 500B amplifier
(Axon Instruments, Union City, CA), and perfused with ND-96 buffer at a rate of 4-6 ml/min.
Buffer perfusion was controlled using a six-channel valve controller (Warner Instruments,
Hamden, CT) interfaced with a Digidata 1322A data acquisition system (Axon Instruments),
and driven by a Dell personal computer (Round Rock, TX). Current responses were recorded
using Clampex 9.2 software (Axon Instruments), and processed using a Bessel (8-pole) low
pass filter with a cutoff at 50 Hz using Clampfit 9.2 software (Axon Instruments).
For each oocyte, the concentration of GABA that produces 5-10% of the maximal current
response (EC5-10 GABA) was determined by measuring the peak current responses evoked by
a range of GABA concentrations (in ND-96 buffer) and comparing them to the maximal peak
current response evoked by 1 mM GABA. The effect of carboetomidate on EC5-10 GABA-
evoked currents was then assessed by first perfusing the oocyte with EC5-10 GABA for 90 s
and measuring the control peak evoked current. After a 5 min recovery period, the oocyte was
perfused with carboetomidate for 90 s and then with EC5-10 GABA plus carboetomidate for
90 s and the peak evoked current was measured again. After a 15 min recovery period, the
control experiment (i.e. no carboetomidate) was repeated to test for reversibility. A longer
recovery period after carboetomidate exposure was used to facilitate washout of the drug. The
peak current response in the presence of carboetomidate was then normalized to the average
peak current response of the two control experiments. Carboetomidate-induced potentiation
was quantified from the normalized current responses in the presence versus absence of
carboetomidate.
Rat Hemodynamics
The effects of hypnotics on rat hemodynamics were defined as previously described. 20
Femoral arterial catheters, tunneled between the scapulas, were preimplanted by the vendor
(Charles River Laboratories). Animals were fully recovered from the placement procedure
upon arrival. During housing and between studies, catheter patency was maintained with a
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heparin (500 U/ml) and hypertonic (25%) dextrose locking solution, which was withdrawn
prior to each use and replaced just after.
On the day of study and following weighing and lateral tail vein IV catheter placement, rats
were restrained in the acrylic tube with a tail exit port and allowed to acclimate for
approximately 10 to 20 min prior to data collection. The signal from the pressure transducer
(TruWave, Edwards Lifesciences, Irvine, CA) was amplified using a custom built amplifier
(AD620 operational amplifier, Jameco Electronics, Belmont, CA) and digitized (1 kHz) using
a USB-6009 data acquisition board (National Instruments, Austin, TX) without additional
filtering. All data were acquired and analyzed using LabView Software (version 8.5 for
Macintosh OS X; National Instruments).
Data used for blood pressure analysis were recorded for 5 min immediately prior to hypnotic
administration and for 15 min thereafter. Carboetomidate (40 mg/ml) dissolved in DMSO,
etomidate (5.7 mg/ml) dissolved in DMSO, or DMSO vehicle alone as a control was
administered through the tail vein catheter followed by approximately 1 ml normal saline flush.
Inhibition of In Vitro Cortisol Synthesis
In vitro cortisol synthesis was measured using the human adrenocortical cell line H295R (NCI-
H295R; ATCC #CRL-2128). Aliquots of 105 cells per well were grown in 12-well culture
plates with 2 ml of growth medium (Dulbecco’s Modified Eagle Medium/F12 supplemented
with 1% insulin, transferrin, selenium, and linoleic acid, 2.5% NuSerum, and Pen/Strep). When
cells reached near confluence (typically 48-72 hr), the growth medium was replaced with assay
medium (Dulbecco’s Modified Eagle Medium/F12 supplemented with 0.1% insulin,
transferring, selenium containing antibiotics and 20 μM forskolin) that contained etomidate or
carboetomdiate. After 48 hr, 1.2 ml of assay medium was collected from each well, centrifuged
to pellet any cells or debris, and the cortisol concentration in the supernatant quantified by
ELISA using commercially available 96-well kits based on horseradish peroxidase-conjugated
cortisol in a competitive antibody binding assay (R&D Systems, Minneapolis, MN, #KGE008).
Rat Adrenocortical Suppression
Immediately following weighing and IV catheter placement, dexamethasone (0.2 mg/kg IV;
American Regent, Shirley, NY) was administered to each rat to inhibit endogenous
adrenocorticotropic hormone (ACTH) release, to suppress baseline corticosterone production,
and to inhibit the variable stress response to restraint and handling. Two hours following
dexamethasone treatment, blood was drawn (for baseline measurement of serum corticosterone
concentration) and a second dose of dexamethasone (0.2 mg/kg) was administered along with
IV carboetomidate, etomidate, or DMSO vehicle as a control. The concentrations of
carboetomidate and etomidate in DMSO were 40 mg/ml and 5.7 mg/ml, respectively.
Immediately after hypnotic or vehicle administration, ACTH1-24 (25 μg/kg; Sigma-Aldrich
Chemical Co, St. Louis, MO) was given intravenously to stimulate corticosterone production.
Fifteen minutes later, a second blood sample was drawn to measure the ACTH1-24-stimulated
serum corticosterone concentration. ACTH1-24 was dissolved in 1 mg/ml in deoxygenated
water as stock, aliquoted, and frozen (−20 °C); a fresh aliquot was thawed just prior to each
use. Rats in all three groups (carboetomidate, etomidate and vehicle) received the same volume
of DMSO (350 μl/kg).
Corticosterone concentrations in blood serum were determined as previously reported. 20 Blood
samples were allowed to clot at room temperature (10 to 60 min) before centrifugation at 3500g
for 5 min. Serum was carefully expressed from any resulting superficial fibrin clot using a
clean pipette tip prior to a second centrifugation at 3500g for 5 min. Following the second
centrifugation, the resultant clot-free serum layer was transferred to a fresh vial for a final,
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high-speed centrifugation (16000g, for 5 min) to pellet any contaminating red blood cells or
particulates. The serum was transferred to a clean vial and promptly frozen (−20 °C) pending
corticosterone measurement. Following thawing and heat inactivation of corticosterone
binding globulins (65 °C for 20 min), serum baseline and ACTH1-24 stimulated corticosterone
concentrations were quantified using an Enzyme-Linked ImmunoSorbent Assay (ELISA)
(Diagnostic Systems Laboratories, Webster, TX) and a 96-well plate reader (Molecular
Devices, Sunnyvale, CA).
Statistical Analysis
All data are reported as mean +/− SD. Statistical analysis and curve fitting (using linear or
nonlinear least squares regression) were done using either Prism v4.0 for the Macintosh
(GraphPad Software, Inc., LaJolla, CA) or Igor Pro 4.01 (Wavemetrics, Lake Oswego, OR).
P-value < 0.05 indicates statistical significance unless otherwise indicated. For multiple
comparisons of physiological data derived from rats, we performed a one-way or two-way
analysis of variance (ANOVA) followed by a Bonferroni post–test (which relies on an unpaired
t-test with a Bonferroni correction).
Results
Loss of Righting Reflexes in Tadpoles and Rats by Carboetomidate
Figure 2A shows the carboetomidate concentration-response relationship for LORR in
Xenopus laevis tadpoles. The fraction of tadpoles that had LORR increased with
carboetomidate concentration and at the highest concentrations studied (10 – 40 μM) all
tadpoles had LORR. All tadpoles that had LORR recovered their righting reflexes when
removed from carboetomidate and returned to fresh water. From the concentration-response
data, carboetomidate’s anesthetic EC50 was determined to be 5.4 ± 0.5 μM.
Intravenous administration of carboetomidate also produced LORR in Sprague Dawley rats.
Figure 2B shows the carboetomidate dose-response relationship for LORR in rats following
IV bolus administration. The fraction of rats that had LORR increased with the dose. At the
highest doses, all rats had LORR and there was no obvious toxicity. From these data, the
ED50 for LORR was determined to be 7 ± 2 mg/kg. We noted that the onset time for LORR
with carboetomidate was slower than we had previously observed with etomidate. 20 We
quantified this difference using equi-hypnotic doses of carboetomidate and etomidate (28 mg/
kg and 4 mg/kg, respectively; 4 X ED50 for LORR). 20 The onset time for LORR with
carboetomidate was 33 ± 22 sec (n = 10; range 10 – 63 sec) as compared to 4.5 ± 0.6 sec (n =
4; range 4 – 5 sec) with etomidate.
Figure 3 shows the relationship between the carboetomidate dose and the duration of LORR
following IV bolus administration to Sprague Dawley rats. The duration of LORR increased
approximately linearly with the logarithm of the dose with a slope of 16 ± 4 min/(log mg/kg).
Modulation by Carboetomidate of Wild-type α1β2γ2L and Etomidate-insensitive
α1β2M286Wγ2L GABAA receptors
Figure 4 shows representative electrophysiological traces elicited by EC5-10 GABA in the
absence or presence of 10 μM carboetomidate. Figure 4A shows traces that were mediated by
wild-type α1β2γ2L GABAA receptors whereas Figure 4B shows traces that were mediated by
etomidate-insensitive mutant α1β2(M286W)γ2L GABAA receptors. Carboetomidate
significantly enhanced currents mediated by wild-type receptors (390 ± 80%) but did not
enhance currents mediated etomidate-insensitive mutant receptors (−9 ± 16%).
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Hemodynamic Actions of Carboetomidate Versus Etomidate in Rats
Figure 5 shows the effects of 14 mg/kg carboetomidate (n=7), 2 mg/kg etomidate (n=6), and
DMSO vehicle (n=4) on mean arterial blood pressure in rats. For carboetomdiate and
etomidate, these are equi-hypnotic doses. During the study period, carboetomidate’s effect on
mean blood pressure was not significantly greater than that of DMSO vehicle alone, (P > 0.05
by two-way ANOVA). However at times from 30 to 210 sec following administration,
etomidate significantly reduced mean blood pressure relative to vehicle. Baseline mean blood
pressures for vehicle, carboetomidate, and etomidate groups were similar (P = 0.15 by
ANOVA) at 114+/−5, 116+/−9, and 127+/−17 mmHg, respectively.
Inhibition by Carboetomidate and Etomidate of Human Adrenocortical Carcinoma Cell
Cortisol Synthesis
Figure 6 shows the carboetomidate and etomidate concentration-response curves for inhibition
of cortisol synthesis by human adrenocortical cells. Although both hypnotics inhibited cortisol
synthesis in a concentration-dependent manner, the concentration ranges over which this
inhibition occurred differed by three orders of magnitude. The half maximal inhibitory
concentration for carboetomidate and etomidate were calculated from these data sets to be 2.6
± 1.5 μM and1.3 ± 0.2 nM, respectively.
Adrenocortical Suppression in Rats Upon Administration of Carboetomidate Versus
Etomidate
Serum corticosterone concentrations were measured in dexamethasone pre-treated rats before
(baseline) and 15 minutes after they received ACTH1-24 and carboetomidate, etomidate, or
DMSO vehicle control. Baseline serum corticosterone concentrations in rats (n=12) averaged
39 ± 49 ng/ml and were not significantly different among the three groups (carboetomidate,
etomidate, and control). Administration of ACTH1-24 stimulated adrenocortical steroid
production in all three groups. However figure 7 shows that serum corticosterone
concentrations varied among the three groups 15 minutes after ACTH1-24 administration. Rats
given carboetomidate had serum corticosterone concentrations that were significantly higher
than those given an equi-hypnotic dose of etomidate and not significantly different from those
given vehicle.
Discussion
Carboetomidate is a pyrrole analogue of etomidate that retains etomidate’s hypnotic action,
GABAA receptor modulatory activity, and hemodynamic stability. However, it is three orders
of magnitude less potent an inhibitor of adrenocortical cortisol synthesis than etomidate and
unlike etomidate, it does not suppress adrenocortical function in rats at hypnotic doses.
Etomidate suppresses adrenocortical function primarily by inhibiting 11β-hydroxylase
(CYP11B1), a member of the cytochrome P450 superfamily of enzymes. 11β-hydroxylase is
required for the synthesis of cortisol, corticosterone, and aldosterone. This suppression occurs
at very low etomidate concentrations, which is thought to reflect very high affinity of etomidate
to the enzyme’s active site. 11,25 We designed carboetomidate based on the hypothesis that
etomidate binds with high affinity to 11β-hydroxylase because the basic nitrogen in its
imidazole ring coordinates with the active site’s heme iron. This interaction has been observed
in the binding of other imidazole-containing drugs to various cytochrome P450 enzymes using
crystallographic techniques. For example, the inhibitor 4-(4-chlorophenyl)imidazole binds to
the enzyme 2B4’s active site in a single orientation with the basic nitrogen of its imidazole
ring coordinated to the enzyme’s heme iron at a bond distance of 2.14 Å. 22 This binding
triggers a conformational transition in which the enzyme closes tightly around the bound ligand.
Similarly, imidazole-containing antifungal agents bind within the active sites of CYP130 and
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CYP121 where they form a coordination bond between their basic nitrogens and the enzymes’
heme iron. 23,24 Evidence of such coordination has also been found using spectroscopic
techniques as the heme group serves as a chromophore that undergoes a characteristic spectral
shift when a coordination bond is formed with an imidazole-containing inhibitor. 23,27-29
Although etomidate’s interactions with 11β-hydroxylase have not been defined experimentally
using crystallographic or spectroscopic techniques, in silico homology modeling suggests that
coordination between the hypnotic’s basic nitrogen and the enzyme’s heme iron also
contributes to high affinity binding. 25
We used an adrenocortical carcinoma cell assay to compare the inhibitory potencies of
carboetomidate and etomidate. This assay has previously been used to compare the potencies
with which drugs inhibit the synthesis of adrenocortical steroids. 30-32 Our studies showed
that carboetomidate is three orders of magnitude less potent an inhibitor of cortisol synthesis
than is etomidate. This is consistent with an important role for the hypnotic’s basic nitrogen
in stabilizing binding to the enzyme and provides strong evidence that high affinity binding of
etomidate to 11β-hydroxylase can be designed out of etomidate by replacing this nitrogen with
other chemical groups (in this case, CH) that cannot coordinate with heme iron. As a
consequence of its low adrenocortical inhibitory potency, carboetomidate failed to inhibit
ACTH1-24-stimulated production of corticosterone in rats when given as a bolus at a hypnotic
dose.
Although carboetomidate is three orders of magnitude less potent an inhibitor of in vitro cortisol
synthesis than is etomidate, it is only modestly less potent as a hypnotic. It has 1/3rd and
1/7th the hypnotic potency of etomidate in tadpoles 33 and rats 20, respectively. These results
provide proof-of-principle that one may alter anesthetic structure in order to dramatically
reduce potency for producing an undesirable side effect without greatly impacting hypnotic
potency.
In common with etomidate, carboetomidate significantly enhances the function of wild-type
α1β2γ21 GABAA receptors.34 Thus, it seems very likely that carboetomidate also produces
hypnosis via actions on the GABAA receptor. Previous electrophysiological studies of the
GABAA receptor have shown that a mutation in the beta subunit at the putative etomidate
binding site (M286W) nearly completely abolishes etomidate enhancement. 35 Our studies
show that this mutation also abolishes enhancement by carboetomidate, suggesting that
carboetomidate modulates GABAA receptor function by binding to the same site on the
GABAA receptor as etomidate.
The magnitude of potentiation that we observed with 10 μM carboetomidate (390 ± 80%) in
the present study is no greater than that observed in our previous study with 4 μM etomidate
(660 ± 240%). This implies that carboetomidate is less potent and/or efficacious at the
GABAA receptor than is etomidate. This may explain why a higher concentration (in our
tadpole assay) and dose (in our rat assay) of carboetomidate than etomidate is needed to produce
LORR. It also indicates that the basic nitrogen in etomidate’s imidazole ring contributes
modestly to etomidate’s action on GABAA receptors.
The onset of LORR was slower with carboetomidate than etomidate. The reason for this is
unclear. However as both hypnotics potentiate the GABAA receptor, it seems likely that onset
is delayed because carboetomidate reaches its site of action in the brain more slowly than
etomidate.
Carboetomidate was conceived as a pharmacodynamic solution to the problem of etomidate-
induced adrenocortical suppression as it was designed not to bind to 11β-hydroxylase with
high affinity. We recently described the results of studies on methoxycarbonyl etomidate, an
etomidate analogue developed as a pharmacokinetic solution to this same problem. 20
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Methoxycarbonyl etomidate is very rapidly metabolized by esterases and, therefore, produces
hypnosis of extremely short duration and does not cause prolonged suppression of
adrenocortical function following administration. In contrast, carboetomidate produces
hypnosis that is similar in duration to etomidate and propofol (when given at equivalent
multiples of their respective ED50 values for LORR) without inhibiting steroid synthesis at a
hypnotic dose.
Supplementary Material
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Appendix 1
Synthesis of (R)-Ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate
(carboetomidate)
Following a procedure described for Mitsunobu alkylation of imidazoles11, a solution of (S)-1-
phenylethanol (135 mg, 1.10 mmol, >99% entaniomeric ratio) in dry tetrahydrofuran (2 ml)
was added dropwise to a stirred solution of ethyl 1H-pyrrole-2-carboxylate (140 mg, 1.00
mmol) and triphenylphosphine (340 mg, 1.30 mmol) in dry THF (3 ml) in an argon atmosphere
at room temperature (Figure 8). Then a solution of di-tert-butyl azodicarboxylate (304 mg,
1.32 mmol) in dry THF (2 ml) was added, and the reaction mixture was allowed to stir at room
temperature overnight. The reaction mixture was concentrated under reduced pressure. The
residue was mixed with diethyl ether (5 ml) and stirred for 2 h. The residue (Ph3PO and hydrazo
ester) were collected and washed with diethyl ether (3 × 2 ml). The filtrate was evaporated
under reduced pressure to yield a residue, which was purified by flash chromatography
(hexanes/CH2Cl2 = 7:3) on silica gel to give a colorless viscous liquid (71 mg, 29% yield): IR
(KBr, cm−1): 737, 1106, 1231, 1700, 2980, 3328; 1H NMR (500 MHz, CDCl3): δ 1.30 (t, J =
7.5 Hz, 3H), 1.80 (d, J = 7.0 Hz, 3H), 4.17–4.28 (m, 2H), 6.17 (dd, J = 4.0, 3.0 Hz, 1H), 6.60
(q, J = 7.0 Hz, 1H), 6.98–7.01 (m, 2H), 7.12–7.14 (m, 2H), 7.20–7.25 (m, 1H), 7.28–7.32 (m,
2H); 13C NMR (500 MHz, CDCl3): δ 14.6, 22.3, 55.5, 60.0, 108.5, 118.5, 122.6, 125.5, 126.4,
127.5, 128.7, 143.3, 161.4; LC-MS observed 244.10, calculated 244.10 for C15H18NO2 (M +
H); Analytical calculation for C, 74.05; H, 7.04; N, 5.76. Found: C, 74.25; H, 6.94; N, 5.66.
The final product was determined to be essentially enantiomerically pure (>99% ee) by chiral
high-pressure liquid chromatography analysis utilizing a AD-H column, isocratic eluent of
hexane and isopropanol (97:3), a flow rate of 1 ml/min and detection at l = 220 nm. See figure,
Supplemental Digital Content 1, which shows the analysis of enantiomerically pure
carboetomidate produced as described above using (S)-1-phenylethanol. For comparison, the
figure also shows the analysis of racemic carboetomidate produced in a similar manner using
racemic 1-phenylethanol.
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Figure 1.
(A) Hypothesized attractive interaction between the basic nitrogen in etomidate’s imidazole
ring and the heme iron at 11β-hydroxylase’s active site. (B) Structure of carboetomidate.
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Figure 2.
(A) Carboetomidate concentration-response curve for loss of righting reflex (LORR) in
tadpoles. Each data point represents the result from a single tadpole. The curve is a fit of the
data set using the method of Waud 26 yielding an EC50 of 5.4 ± 0.5 μM. (B) Carboetomidate
dose-response curve for LORR in rats. Each data point represents the results from a single rat.
The curve is a fit of the data set using the method of Waud 26 yielding an ED50 of 7 ± 2 mg/
kg.
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Figure 3.
The duration loss of righting reflex (LORR) in rats increased with the logarithm of the
carboetomidate dose. The slope of this relationship was 16 ± 4 min/(log mg/kg) (r2 = 0.64).
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Figure 4.
Carboetomidate modulation of human γ-aminobutyric acid type A receptor function. (A)
Representative traces showing reversible enhancement by 10 μM carboetomidate of currents
mediated by wild-type receptors when evoked by EC5-10 γ-aminobutyric acid. (B)
Representative traces showing minimal of enhancement by 10 μM carboetomidate of currents
mediated by etomidate-insensitive mutant receptors when evoked by EC5-10 γ-aminobutyric
acid.
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Figure 5.
The effects of 14 mg/kg carboetomidate (n=7), 2 mg/kg etomidate (n=6), and dimethyl
sulfoxide (DMSO) vehicle alone (n=4) on mean blood pressure in rats. Hypnotics were given
at doses equal to twice their respective ED50s for loss of righting reflex in DMSO vehicle. All
rats received the same quantity of DMSO vehicle (350 μl/kg). Hypnotic in DMSO vehicle or
DMSO vehicle alone was injected at time 0. Each data point represents the average (± SD)
change in mean blood pressure during each 30 s epoch. *, P < 0.05 versus DMSO vehicle alone.
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Figure 6.
The effects of carboetomidate and etomidate on cortisol synthesis by human adrenocortical
carcinoma cells. The curves are fits of each data set to a Hill equation yielding half maximal
inhibitory concentrations of 2.6 ± 1.5 μM and1.3 ± 0.2 nM for carboetomidate and etomidate,
respectively. Each data point is the average (± SD) of three measurements. The control cortisol
concentration was 0.86 ± 020 ng/ml.
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Figure 7.
Adrenocorticotropic hormone1-24-stimulated serum corticosterone concentrations in rats 15
min after administration of vehicle, 2 mg/kg etomidate, or 14 mg/kg carboetomidate. Hypnotics
were given at doses equal to twice their respective ED50s for loss of righting reflex. Four rats
were studied in each group. Average serum corticosterone concentrations (± SD) were 390 ±
50 ng/ml, 120 ± 80 ng/ml, and 330 ± 70 ng/ml following administration of dimethyl sulfoxide
vehicle (control), etomidate, and carboetomidate, respectively. *, P < 0.05, N.S., no significant
difference.
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Figure 8.
Synthesis of carboetomidate
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